ZeroHarm Sciences, a player in the nutraceutical market, has raised Rs 65 crore ($7.15 million) in its Series A funding round, as reported by Entrackr : Latest Posts. The investment, led by Kotak Alternate Asset Managers Limited and Alkemi Growth Capital, aims to support the company’s growth initiatives.
Established in 2020 by Sachin and Shweta Darbarwar, ZeroHarm Sciences specializes in developing plant-based health supplements using nano formulation technology. This approach enhances bioavailability and facilitates controlled release at lower dosages.
By integrating ayurveda with advanced nano technology, the company aims to create India’s premier health platform. ZeroHarm Sciences focuses on substantiating supplement efficacy through measurable consumer health outcomes.
With an extensive network of over 10,000 farmers in Northeast India and the Himalayas, the company controls the entire value chain from sourcing medicinal plants to product delivery. ZeroHarm Sciences has also patented its nano formulations for various health compositions.
The company offers a diverse range of over 60 products catering to different health needs, including diabetes management, heart health, immunity, and women’s wellness. Its presence across multiple e-commerce platforms has enabled the brand to reach a wide customer base, serving over 300,000 individuals.
This funding round will support ZeroHarm Sciences’ expansion into international markets such as the USA, the UK, and the Middle East, as well as bolster its research and manufacturing capabilities.
Source: Entrackr : Latest Posts